Interferon Beta and Glatiramer Acetate Therapy

Interferon beta and glatiramer acetate induce proliferation of Schwann cells in vitro.

Techniques as well as substances capable of stimulating cultured Schwann cell (SC) proliferation are needed for future therapeutical applications. In this work, the effects of interferon beta (IFNbeta) and glatiramer acetate (GA) on SC cultures were tested, with interest on the growth curve and potential proliferative effects. Primary cultures were prepared from the sciatic nerves of neonatal r...

Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort.

INTRODUCTION Many patients with multiple sclerosis (MS) are currently receiving treatment with interferon beta (IFNb) and glatiramer acetate (GA). Identifying nonresponders patients is important to define therapy strategies. Several criteria for treatment response to IFNb and GA have been proposed. OBJECTIVE It was to investigate the response to treatment with IFNb-1a, IFNb-1b and GA among re...

Multiple sclerosis-associated fatigue during disease-modifying treatment with natalizumab, interferon-beta and glatiramer acetate.

Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.

IMPORTANCE After multiple sclerosis (MS) relapse while a patient is receiving an injectable disease-modifying drug, many physicians advocate therapy switch, but the relative effectiveness of different switch decisions is often uncertain. OBJECTIVE To compare the effect of the oral immunomodulator fingolimod with that of all injectable immunomodulators (interferons or glatiramer acetate) on re...

Therapy with glatiramer acetate for multiple sclerosis.

BACKGROUND Some clinical data have shown that glatiramer acetate (Copaxone), a synthetic amino acid polymer empirically found to suppress experimental allergic encephalomyelitis (EAE), an animal model of MS, might help improve the outcome of patients with multiple sclerosis (MS). OBJECTIVES We performed a Cochrane review of all randomised, placebo-controlled trials of glatiramer acetate in MS...